James J Beaudoin1, Tiebing Liang2, Qing Tang3, Bubu A Banini4, Vijay H Shah5, Arun J Sanyal4, Naga P Chalasani2, Samer Gawrieh2. 1. Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. 2. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. 3. Department of Biostatistics, Indiana University School of Medicine and Richard M. Fairbanks School of Public Health, Indianapolis, IN, USA. 4. Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, USA. 5. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Alcoholic hepatitis (AH) is a severe and life-threatening alcohol-associated liver disease. Only a minority of heavy drinkers acquires AH and severity varies among affected individuals, suggesting a genetic basis for the susceptibility to and severity of AH. METHODS: A cohort consisting of 211 patients with AH and 176 heavy drinking controls was genotyped for five variants in five candidate genes that have been associated with chronic liver diseases: rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3), rs72613567 in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), rs58542926 in transmembrane 6 superfamily member 2 (TM6SF2), rs641738 in membrane bound O-acyltransferase domain containing 7 (MBOAT7), and a copy number variant in the haptoglobin (HP) gene. We tested the effects of individual variants and the combined/interacting effects of variants on AH risk and severity. RESULTS: We found significant associations between AH risk and the risk alleles of rs738409 (p = 0.0081) and HP (p = 0.0371), but not rs72613567 (p = 0.3132), rs58542926 (p = 0.2180), or rs641738 (p = 0.7630), after adjusting for patient's age and sex. A multiple regression model indicated that PNPLA3 rs738409:G [OR = 1.59 (95% CI: 1.15-2.22), p = 0.0055] and HP*2 [OR = 1.38 (95% CI: 1.04-1.82), p = 0.0245], when combined and adjusted for age and sex also had a large influence on AH risk among heavy drinkers. In the entire cohort, variants in PNPLA3 and HP were associated with increased total bilirubin and Model for End-stage Liver Disease (MELD) score, both measures of AH severity. The HSD17B13 rs72613567:AA allele was not found to reduce risk of AH in patients carrying the G allele of PNPLA3 rs738409 (p = 0.0921). CONCLUSION: PNPLA3 and HP genetic variants increase AH risk and are associated with total bilirubin and MELD score, surrogates of AH severity.
BACKGROUND: Alcoholic hepatitis (AH) is a severe and life-threatening alcohol-associated liver disease. Only a minority of heavy drinkers acquires AH and severity varies among affected individuals, suggesting a genetic basis for the susceptibility to and severity of AH. METHODS: A cohort consisting of 211 patients with AH and 176 heavy drinking controls was genotyped for five variants in five candidate genes that have been associated with chronic liver diseases: rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3), rs72613567 in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), rs58542926 in transmembrane 6 superfamily member 2 (TM6SF2), rs641738 in membrane bound O-acyltransferase domain containing 7 (MBOAT7), and a copy number variant in the haptoglobin (HP) gene. We tested the effects of individual variants and the combined/interacting effects of variants on AH risk and severity. RESULTS: We found significant associations between AH risk and the risk alleles of rs738409 (p = 0.0081) and HP (p = 0.0371), but not rs72613567 (p = 0.3132), rs58542926 (p = 0.2180), or rs641738 (p = 0.7630), after adjusting for patient's age and sex. A multiple regression model indicated that PNPLA3 rs738409:G [OR = 1.59 (95% CI: 1.15-2.22), p = 0.0055] and HP*2 [OR = 1.38 (95% CI: 1.04-1.82), p = 0.0245], when combined and adjusted for age and sex also had a large influence on AH risk among heavy drinkers. In the entire cohort, variants in PNPLA3 and HP were associated with increased total bilirubin and Model for End-stage Liver Disease (MELD) score, both measures of AH severity. The HSD17B13 rs72613567:AA allele was not found to reduce risk of AH in patients carrying the G allele of PNPLA3 rs738409 (p = 0.0921). CONCLUSION: PNPLA3 and HP genetic variants increase AH risk and are associated with total bilirubin and MELD score, surrogates of AH severity.
Authors: Felix Stickel; Philipp Lutz; Stephan Buch; Hans Dieter Nischalke; Ines Silva; Vanessa Rausch; Janett Fischer; Karl Heinz Weiss; Daniel Gotthardt; Jonas Rosendahl; Astrid Marot; Mona Elamly; Marcin Krawczyk; Markus Casper; Frank Lammert; Thomas W M Buckley; Andrew McQuillin; Ulrich Spengler; Florian Eyer; Arndt Vogel; Silke Marhenke; Johann von Felden; Henning Wege; Rohini Sharma; Stephen Atkinson; Andre Franke; Sophie Nehring; Vincent Moser; Clemens Schafmayer; Laurent Spahr; Carolin Lackner; Rudolf E Stauber; Ali Canbay; Alexander Link; Luca Valenti; Jane I Grove; Guruprasad P Aithal; Jens U Marquardt; Waleed Fateen; Steffen Zopf; Jean-Francois Dufour; Jonel Trebicka; Christian Datz; Pierre Deltenre; Sebastian Mueller; Thomas Berg; Jochen Hampe; Marsha Y Morgan Journal: Hepatology Date: 2020-05-20 Impact factor: 17.425
Authors: Dalila Pinto; Katayoon Darvishi; Xinghua Shi; Diana Rajan; Diane Rigler; Tom Fitzgerald; Anath C Lionel; Bhooma Thiruvahindrapuram; Jeffrey R Macdonald; Ryan Mills; Aparna Prasad; Kristin Noonan; Susan Gribble; Elena Prigmore; Patricia K Donahoe; Richard S Smith; Ji Hyeon Park; Matthew E Hurles; Nigel P Carter; Charles Lee; Stephen W Scherer; Lars Feuk Journal: Nat Biotechnol Date: 2011-05-08 Impact factor: 54.908
Authors: Noura S Abul-Husn; Xiping Cheng; Alexander H Li; Yurong Xin; Claudia Schurmann; Panayiotis Stevis; Yashu Liu; Julia Kozlitina; Stefan Stender; G Craig Wood; Ann N Stepanchick; Matthew D Still; Shane McCarthy; Colm O'Dushlaine; Jonathan S Packer; Suganthi Balasubramanian; Nehal Gosalia; David Esopi; Sun Y Kim; Semanti Mukherjee; Alexander E Lopez; Erin D Fuller; John Penn; Xin Chu; Jonathan Z Luo; Uyenlinh L Mirshahi; David J Carey; Christopher D Still; Michael D Feldman; Aeron Small; Scott M Damrauer; Daniel J Rader; Brian Zambrowicz; William Olson; Andrew J Murphy; Ingrid B Borecki; Alan R Shuldiner; Jeffrey G Reid; John D Overton; George D Yancopoulos; Helen H Hobbs; Jonathan C Cohen; Omri Gottesman; Tanya M Teslovich; Aris Baras; Tooraj Mirshahi; Jesper Gromada; Frederick E Dewey Journal: N Engl J Med Date: 2018-03-22 Impact factor: 91.245
Authors: Hamish Innes; Stephan Buch; Sharon Hutchinson; Indra Neil Guha; Joanne R Morling; Eleanor Barnes; Will Irving; Ewan Forrest; Vincent Pedergnana; David Goldberg; Esther Aspinall; Stephan Barclay; Peter C Hayes; John Dillon; Hans Dieter Nischalke; Philipp Lutz; Ulrich Spengler; Janett Fischer; Thomas Berg; Mario Brosch; Florian Eyer; Christian Datz; Sebastian Mueller; Teresa Peccerella; Pierre Deltenre; Astrid Marot; Michael Soyka; Andrew McQuillin; Marsha Y Morgan; Jochen Hampe; Felix Stickel Journal: Gastroenterology Date: 2020-06-16 Impact factor: 33.883
Authors: Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs Journal: Nat Genet Date: 2008-09-25 Impact factor: 38.330
Authors: Alexis C Edwards; Kristina Sundquist; Jan Sundquist; Kenneth S Kendler; Sara Larsson Lönn Journal: Alcohol Clin Exp Res Date: 2021-12-19 Impact factor: 3.455